US biopharmaceutical company Amgen (NASDAQ:AMGN) announced on Monday that it has received marketing authorisation from the European Commission for IMDYLLTRA (tarlatamab) as a monotherapy to treat adults with extensive-stage small cell lung cancer (ES-SCLC) who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy.
This approval was based on results from DeLLphi-304, the first global Phase 3 trial to demonstrate a significant survival benefit over chemotherapy in this setting.
In the trial, IMDYLLTRA reduced the risk of death by 40% and significantly extended median overall survival (OS) by more than five months compared to standard of care (SOC) chemotherapy as a treatment for patients with ES-SCLC who progressed on or after one line of platinum-based chemotherapy.
Ribo submits Phase 2 trial application for RBD1119 to European regulator
US FDA extends review timeline for AstraZeneca's camizestrant application
Orsini to chosen as contracted specialty pharmacy for Gilead's Hepcludex (bulevirtide-gmod)
Merz Therapeutics and Kvvit sign exclusive agreement for INBRIJA in Greater China
Lundbeck's Vyepti (eptinezumab) receives South Korean approval for preventive treatment of migraine
Eli Lilly reports positive Phase 1b results for VERVE-102
Dicot Pharma submits FDA application for LIB-01 phase 2b study
European Commission approves Pharming's Joenja for APDS treatment in the EU
Caliway Biopharmaceuticals receives US FDA IND clearance for second global Phase 3 study of CBL-514
AbbVie's MAVIRET receives positive opinion from European regulator
Enhertu recommended for EU approval in previously treated HER2 positive metastatic solid tumours
Bayer's KERENDIA receives FDA priority review for type 1 diabetes and kidney disease treatment
Upsher-Smith launches generic Cyclosporine Ophthalmic Emulsion 0.05%